Literature DB >> 1649268

Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer.

S E Ettinghausen1, M E Burt.   

Abstract

Although adrenal metastases are frequently noted with non-small-cell lung cancer (NSCLC) at autopsy, their incidence in patients with operable NSCLC is unclear. We prospectively assessed consecutive patients with otherwise operable NSCLC for the incidence and histology of unilateral adrenal masses. Assessment included blood chemistries, lung function tests, bronchoscopy, chest x-ray, bone scan, and computed tomography (CT) of the head, chest, and upper abdomen. Of 246 patients with otherwise operable NSCLC, 10 (4.1%) had a unilateral adrenal mass. Unilateral adrenal masses were needle-aspirated under CT control. If cytology was nondiagnostic, adrenalectomy was performed. Four (40%) of 10 patients had adrenal metastases proven by needle aspiration. Of the six (60%) patients with benign unilateral adrenal masses, one was demonstrated by needle aspiration. In the other five patients, a nondiagnostic needle aspiration led to adrenalectomy, which yielded two adenomas, two hyperplastic nodules, and one hemorrhagic cyst. There was no significant difference between the patients with benign and metastatic unilateral adrenal masses with respect to patient age or stage and size of adrenal mass. Patients with benign unilateral adrenal masses underwent curative resection of their NSCLC and had significantly prolonged survival compared with patients with metastatic unilateral adrenal masses treated with chemotherapy (P = .037). Median survival of patients with benign and metastatic unilateral adrenal masses was greater than 30 months and 9 months, respectively. In conclusion, the presence of unilateral adrenal masses in patients with otherwise operable NSCLC should not preclude thoracotomy without pathologic proof of metastatic disease.

Entities:  

Mesh:

Year:  1991        PMID: 1649268     DOI: 10.1200/JCO.1991.9.8.1462

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  22 in total

Review 1.  Management of non-small cell lung cancer with oligometastasis.

Authors:  Liza C Villaruz; Gregory J Kubicek; Mark A Socinski
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

Review 2.  Positron emission tomography/computerized tomography in lung cancer.

Authors:  Ilgin Sahiner; Gulin Ucmak Vural
Journal:  Quant Imaging Med Surg       Date:  2014-06

3.  EUS-B-FNA for Diagnosing Liver and Celiac Metastases in Lung Cancer Patients.

Authors:  Ida Skovgaard Christiansen; Uffe Bodtger; Therese Maria Henriette Naur; Khaliq Ahmad; Jatinder Singh Sidhu; Rafi Nessar; Goran Nadir Salih; Asbjørn Høegholm; Jouke Tabe Annema; Paul Frost Clementsen
Journal:  Respiration       Date:  2019-09-27       Impact factor: 3.580

4.  An unusual case of adrenal failure due to isolated metastases of breast cancer.

Authors:  M V Davì; G Francia; P Brazzarola; M Olivieri; A Petrozziello; A Orsolini; R Petronio; P L Sussi
Journal:  J Endocrinol Invest       Date:  1996 Jul-Aug       Impact factor: 4.256

Review 5.  Surgical approach in oligometastatic non-small cell lung cancer.

Authors:  Davide Patrini; Nikolaos Panagiotopoulos; Benedetta Bedetti; Sofoklis Mitsos; Roberto Crisci; Piergiorgio Solli; Luca Bertolaccini; Marco Scarci
Journal:  Ann Transl Med       Date:  2018-03

6.  FDG-PET and CT characterization of adrenal lesions in cancer patients.

Authors:  Suman Jana; Tong Zhang; David M Milstein; Carmen R Isasi; M Donald Blaufox
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-29       Impact factor: 9.236

7.  Tumor acquisition for biomarker research in lung cancer.

Authors:  Marvaretta Stevenson; Jared Christensen; Debra Shoemaker; Traci Foster; William T Barry; Betty C Tong; Momen Wahidi; Scott Shofer; Michael Datto; Geoffrey Ginsburg; Jeffrey Crawford; Thomas D'Amico; Neal Ready
Journal:  Cancer Invest       Date:  2014-05-09       Impact factor: 2.176

Review 8.  Extended resection for higher-stage non-small-cell lung cancer.

Authors:  J D Luketich; D E van Raemdonck; R J Ginsberg
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 9.  Advanced non-small cell lung cancer.

Authors:  M J Edelman; S L Khanwani
Journal:  Curr Treat Options Oncol       Date:  2001-02

Review 10.  Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.

Authors:  W Zachary Stone; David C Wymer; Benjamin K Canales
Journal:  J Endourol       Date:  2013-10-09       Impact factor: 2.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.